- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Biohaven Ltd.(BHVN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BHVN
11/13/2026: BHVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Biohaven Ltd. is a clinical-stage biopharmaceutical company that develops innovative therapies for neurological, psychiatric, and specialty diseases. The company's main strengths lie in its experienced leadership team, broad clinical pipeline, and proprietary platforms targeting conditions with high unmet medical need. Its primary growth story centers on advancing key assets like troriluzole and taldefgrobep alfa toward potential regulatory approvals. Key risks include ongoing operational cash burn, clinical trial execution uncertainty, and intense competition in the neuroscience space. The stock best suits growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical readouts and regulatory catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Biohaven offers significant upside potential tied to its expansive clinical pipeline and innovative neurology drug candidates. |
| Momentum investor | Strong fit while signal remains positive | Clinical trial readouts and regulatory catalysts frequently trigger sharp short-term momentum shifts in the stock price. |
| Value investor | Weak fit | The company currently lacks consistent positive earnings and commercial revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Biohaven does not pay dividends, directing all cash flow into clinical research and pipeline development. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology equities experience high volatility driven by binary trial outcomes and regulatory decisions. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock valuations fluctuate sharply based on clinical updates, regulatory feedback, and market sentiment. |
| Valuation risk | Medium / high | Valuation relies heavily on future drug approvals rather than current earnings or cash flows. |
| Competition risk (neurology and rare disease therapeutics) | High | The company competes with well-capitalized pharmaceutical firms targeting similar neurological pathways. |
| Business quality | Medium | While backed by experienced science teams, the lack of commercialized revenue streams limits current financial depth. |
| Dividend income | Low / none | No dividend distributions are provided to shareholders. |
| Execution risk | High | Success depends entirely on executing complex clinical trials and securing regulatory approvals. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.09B USD | Price to earnings Ratio - | 1Y Target Price 23.73 |
Price to earnings Ratio - | 1Y Target Price 23.73 | ||
Volume (30-day avg) 3.2M shares | Beta 3.13 | 52 Weeks Range 7.99 - 18.24 | Updated Date 11/15/2026 |
52 Weeks Range 7.99 - 18.24 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.77 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -8.29% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development and Licensing | Potential milestone payments, collaborative research agreements, and future commercial sales of approved drug candidates. | Biohaven is currently a pre-commercial development company aiming to generate future revenue from successful drug approvals. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2.23B | Price to Sales(TTM) - |
Enterprise Value 2.23B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 151.06M | Shares Floating 116.59M |
Shares Outstanding 151.06M | Shares Floating 116.59M | ||
Percent Insiders 12.46 | Percent Institutions 94.72 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

